More importantly, we used the support vector machine (SVM) model integrating APOE genotype, CSF biomarkers (Aβ, Tau, and pTau), and neuroimaging biomarkers (insula volumes and altered regional IFCs) to classify AD spectrum and evaluate classifier performance. This evidence concerns the gene MAPT and Alzheimer disease.